knowledge -WSS

knowledge

author：knowledge 2025-08-22 16:56:02 - browse：374

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： New Ultima Genomics DNA sequencer can read genome for $100

WSS

Surge in Apellis stock fueled by confidence in safety of its eye drug

After Optum profits sink, UnitedHealth makes changes

Biogen’s boardroom scandal saddles CEO with first crisis

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Cognito secures funding to test medical device for Alzheimer's

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Virginia high school admissions case could be legal follow

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Cancer drug shortages should be causing more outrage

Time to name cancers by genetics, not organ of origin, expert says

Tori Bowie and the unacceptable rates of Black maternal death

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Medical records are filled with copy

Biden administration begins canceling student loan debt for 804,000 borrowers

How one medical school became remarkably diverse

Biden administration begins canceling student loan debt for 804,000 borrowers

hotspot

Commercial surrogacy can be ethical, despite pope’s claims

Biden administration opens offers in Medicare drug price negotiations

YouTube cracks down on misinformation on cancer treatment

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Covid misinformation case heads to Supreme Court

Quicker fix for pulse oximeters urged during FDA public meeting

leisure time

leisure time

hotspot

knowledge